Rees, A.; Villamor, E.; Evans, D.; Gooz, M.; Fallon, C.; Mina-Abouda, M.; Disharoon, A.; Eblen, S.T.; Delaney, J.R.
Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer. Genes 2025, 16, 42.
https://doi.org/10.3390/genes16010042
AMA Style
Rees A, Villamor E, Evans D, Gooz M, Fallon C, Mina-Abouda M, Disharoon A, Eblen ST, Delaney JR.
Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer. Genes. 2025; 16(1):42.
https://doi.org/10.3390/genes16010042
Chicago/Turabian Style
Rees, Amy, Evan Villamor, Della Evans, Monika Gooz, Clare Fallon, Mirna Mina-Abouda, Andrew Disharoon, Scott T. Eblen, and Joe R. Delaney.
2025. "Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer" Genes 16, no. 1: 42.
https://doi.org/10.3390/genes16010042
APA Style
Rees, A., Villamor, E., Evans, D., Gooz, M., Fallon, C., Mina-Abouda, M., Disharoon, A., Eblen, S. T., & Delaney, J. R.
(2025). Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer. Genes, 16(1), 42.
https://doi.org/10.3390/genes16010042
